Acrodermatitis Continua Resistant to Etanercept: Therapeutic Challenge and Unfortunate Outcome
June 2008
in “
Journal of the European Academy of Dermatology and Venereology
”
TLDR A man with Acrodermatitis continua did not get better with etanercept treatment, and his condition worsened, suggesting treatment effectiveness may vary by genetics and race.
The document described a 47-year-old man with Acrodermatitis continua of Hallopeau (ACH) who did not improve after treatment with etanercept, among other therapies. His condition, characterized by erythema, pustules, and nail loss, progressed to generalized pustular psoriasis, causing significant pain and disability. This case, along with another from Turkey, suggests that genetic and racial factors may affect the response to etanercept in ACH patients. The authors emphasize the need for more research on the effectiveness of biological agents in treating ACH, acknowledging the difficulty due to the rarity of the condition and the reliance on individual case reports for information.
